full issue - Association of Biotechnology and Pharmacy

Current Trends in Biotechnology and Pharmacy
Vol. 5 (3) 1251-1272 July 2011, ISSN 0973-8916 (Print), 2230-7303 (Online)
1271
Taxonomy, fermentation, isolation and
characterization. J Antibiot (Tokyo),
44:1342-1347.
68. Ihara, M., Ishikawa, K., Fukuroda, T.,
Saeki, T., Funabashi, K., Fukami, T., Suda,
H. and Yano, M. (1992). In vitro biological
profile of a highly potent novel endothelin
(ET) antagonist BQ-123 selective for the
ET A
receptor. J Cardiovasc Pharmacol., 20:
S11-14.
69. Fukami, T., Yamakawa, T., Niiyama, K.,
Kojima, H., Amano, Y., Kanda, F., Ozaki,
S., Fukuroda, T., Ihara, M., Yano, M. and
Ishikawa, K. (1996). Synthesis and
structure-activity relationships of 2-
substituted D-tryptophan-containing
peptidic endothelin receptor antagonists:
importance of the C-2 substituent of the D-
tryptophan residue for endothelin A and B
receptor subtype selectivity. J Med Chem.,
39: 2313-2330.
70. Hochlowski, J.E., Hill, P., Whittern, D.N.,
Scherr, M.H., Rasmussen, R.R., Dorwin,
S.A. and McAlpine, J.B. (1994). Aselacins,
novel compounds that inhibit binding of
endothelin to its receptor. II. Isolation and
elucidation of structures. J Antibiot
(Tokyo), 47: 528-535.
71. Jackson, M., Burres, N.S., Karwowski, J.P.,
Alder, L.A., Humphrey, P.E., Kohl, W.L.
and McAlpine, J.B. (1994). Aselacins,
novel compounds that inhibit binding of
endothelin to its receptor. I. The producing
organism, fermentation and biological
activity. J Antibiot (Tokyo), 47: 523-527
72. Fujimoto, M., Mihara, S., Nakajima, S.,
Ueda, M., Nakamura, M. and Sakurai, K.
(1992). A novel non-peptide endothelin
antagonist isolated from bayberry, Myrica
cerifera. FEBS Lett., 305: 41-44.
73. Maguire, J., Bacon, C., Fujimoto, M. and
Davenport, A. (1994). Myricerone caffeoyl
ester (50-235) is a non-peptide antagonist
selective for human ET A
receptors. J
Hypertens., 12: 675-680.
74. Ohshima, T., Hirata, M., Oda, T., Sasaki,
A. and Shiratsuchi, M. (1994).
Pheophorbide a, a potent endothelin
receptor antagonist for both ET A
and ET B
subtypes. Chem Pharm Bull., 42: 2174-
2176.
75. Caballero-George, C., Vanderheyden,
P.M.L., Solis, P.N., Pieters, L., Shahat,
A.A., Gupta, M.P., Vauquelin, G. and
Vlietinck, A. (2001). Biological screening
of selected medicinal Panamanian plants
by radioligand-binding techniques.
Phytomedicine, 8: 59-70.
76. Caballero-George, C., Vanderheyden,
P.M.L., Okamoto, Y., Masaki, T.,
Mbwambo, Z., Apers, S., Gupta, M.P.,
Pieters, L., Vauquelin, G. and Vlietinck, A.
(2004). Evaluation of bioactive saponins
and triterpenoidal aglycons for the binding
properties on human endothelin ET A
and
angiotensin AT 1
receptors. Phytotherapy
Research, 18: 729-736.
77. Gulavita, N.K., Wright, A.E., McCarthy,
P.J., Pomponi, S.A., Kelly-Borges, M.,
Chin, M. and Sills, M.A. (1993). Isolation
and structure elucidation of 34-
Sulfatobastadin 13, an inhibitor of the
endothelin A receptor, from a marine
sponge of the genus Ianthella. Journal of
Natural Products, 56: 1613-1617.
78. Gao, J., Caballero-George, C., Wang, B.,
Rao, K.V., Shilabin, A.G. and Hamann,
M.T. (2009). 5-OHKF and NorKA,
depsipeptides from a Hawaiian collection
of Bryopsis pennata: binding properties for
Catherina Caballero-George